ARX424 was created by Ambrx through the application of its proprietary protein optimization technology, ReCODE. This second collaboration between the two companies follows a previous agreement announced in
The study evaluated symptomatic progress of US patients involved in the company’s two initial 2003 Phase I-II studies of NX-1207. Patients treated with NX-1207 were followed-up on an
For the year ended December 31, 2008, the company’s cash, cash equivalents, investments and settlement rights associated with certain auction rate securities totaled $215.0 million. Revenues for the
The top-line analysis of data from this study shows that Prulifloxacin met the study objective of superiority to placebo in the resolution of diarrhea, measured by time to
Pfizer said that the decision to terminate these programs will enable the business unit to allocate additional resources to higher-potential development programs as part of its continuing effort
As assessed by independent radiological review, patients with advanced renal cell carcinoma (RCC) treated with AV-951 experienced a 91.7% disease control rate at 16 weeks. The data also
Sumatriptan is a vascular headache suppressant indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes. Sumatriptan succinate
Eisai and Nitto Denko have been developing jointly a transdermal patch formulation of Aricept pursuant to the agreement signed on May 10, 2006. However, after a re-evaluation of
The lintuzumab Phase IIb clinical trial is a randomized, double-blind, placebo-controlled study evaluating whether the combination regimen of lintuzumab and low-dose cytarabine chemotherapy extends overall survival compared to
Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The US
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.